Key Points
- Medpace director Brian Carley sold 5,000 shares at an average price of $608.63, generating $3.04 million and reducing his direct stake by 15.23% to 27,825 shares.
- Medpace exceeded quarterly expectations, reporting $4.25 in EPS and $707.33 million in revenue, with revenue up 17.2% year over year. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
- Analyst sentiment remains cautious: three analysts rate the stock Buy and ten rate it Hold, producing a consensus Hold rating and an average price target of $584.18, below its $620.75 opening price.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) Director Brian Carley sold 5,000 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. This represents a 15.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Medpace Price Performance
Shares of MEDP opened at $620.75 on Friday. The firm has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.73 and a beta of 1.15. The company has a 50-day moving average of $550.16 and a 200 day moving average of $492.71. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period last year, the company posted $3.10 earnings per share. The company's quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on MEDP shares. Truist Financial raised their price objective on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and increased their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $584.18.
Check Out Our Latest Report on Medpace
Hedge Funds Weigh In On Medpace
Large investors have recently made changes to their positions in the business. Johnson Financial Group Inc. purchased a new stake in Medpace in the second quarter valued at about $27,000. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new position in Medpace in the 4th quarter valued at about $30,000. Jones Financial Companies Lllp acquired a new stake in Medpace in the 2nd quarter worth about $30,000. Finally, Allied Private Wealth LLC acquired a new position in shares of Medpace during the second quarter valued at approximately $31,000. 77.98% of the stock is owned by institutional investors and hedge funds.
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
